Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

NCT04407442 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Slow enrollment and change in sponsor direction

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

DRUG: Azacitidine
BIOLOGICAL: Daratumumab
DRUG: Dexamethasone

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]